 | Review waiting, please be patient.
This may take 7 weeks or more, since drafts are reviewed in no specific order. There are 1,335 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
| Submission declined on 30 October 2024 by -noah- (talk). This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by -noah- 26 days ago. |  |
| Submission declined on 30 October 2024 by DoubleGrazing (talk). This submission is not adequately supported by reliable sources. Reliable sources are required so that information can be verified. If you need help with referencing, please see Referencing for beginners and Citing sources. This draft's references do not show that the subject qualifies for a Wikipedia article. In summary, the draft needs multiple published sources that are: Declined by DoubleGrazing 27 days ago.
| |
Comment: This article would be accepted onto Wikipedia if it had significant coverage by three independent, reliable sources. The only source provided that passes is the first source, the Le Temps article. Noah 💬 22:01, 30 October 2024 (UTC)
 | |
| Company type | Société Anonyme |
|---|---|
| Industry | Biopharmaceutical |
| Founded | Barcelona, (1930) |
| Headquarters | Geneva, Switzerland |
Area served | Worldwide |
Key people |
|
| Products | OM-89 |
| Owner | Etienne Jornod (Executive Chairman & Co‑Owner) |
| Website | www |
OM Pharma is a Swiss multinational biopharmaceutical company headquartered in Geneva.
OM Pharma was originally founded in Barcelona in 1930 and later moved its headquarters to Geneva in 1937 under the leadership of Jean-René Ricard, a French Pharmacist. In 2020, the company was acquired by Optimus Holding, led by Etienne Jornod, which committed to significant investments in its research and manufacturing capabilities.[1][2]
The company specialises in the development and commercialization of bacterial lysate-based products., aimed at preventing respiratory and urinary tract infections by training the immune system.[3] OM Pharma's pipeline focuses on future applications of lysates.
In 2021, OM Pharma was awarded the Geneva Economy Award[4]. The independent jury noted OM Pharma’s economic and social policy which aims at the long-term development of the company; all its profits are reinvested in research and development (R&D)[5][6].
- ^ "Etienne Jornod achète une deuxième fois OM Pharma à Genève - Le Temps" (in French). 2020-09-18. ISSN 1423-3967. Retrieved 2024-10-30.
- ^ "Interview avec Etienne Jornod | Board Talk". Deloitte Switzerland (in Swiss French). Retrieved 2024-10-30.
- ^ Leo (2022-02-17). "List of the 3 largest chemical companies from Geneva (Canton)". Research Germany. Retrieved 2024-10-30.
- ^ "OM Pharma Wins Geneva Economy Award". PharmExec. 2021-09-21. Retrieved 2024-11-13.
- ^ "La Gazette du LABORATOIRE - OM Pharma remporte le Prix 2021 de l'économie genevoise". www.gazettelabo.fr. Retrieved 2024-11-13.
- ^ Hernandez, Miguel (2021-09-21). "Le Prix 2021 de l'économie genevoise attribué à OM Pharma" (in French). Retrieved 2024-11-13.